Onconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Acquires 92,554 Shares

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt bought 92,554 shares of Onconetix stock in a transaction dated Wednesday, April 15th. The shares were bought at an average cost of $0.76 per share, for a total transaction of $70,341.04. Following the completion of the transaction, the insider owned 197,052 shares of the company’s stock, valued at approximately $149,759.52. This trade represents a 88.57% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, April 14th, Financial Lp Hrt bought 74,350 shares of Onconetix stock. The shares were bought at an average cost of $0.77 per share, for a total transaction of $57,249.50.

Onconetix Price Performance

Shares of NASDAQ:ONCO traded down $0.01 during trading on Thursday, reaching $0.76. 1,640,803 shares of the company were exchanged, compared to its average volume of 4,878,667. The firm has a market capitalization of $498,300.00, a PE ratio of 0.00 and a beta of 3.63. The business’s fifty day simple moving average is $3.07 and its 200-day simple moving average is $8.97. Onconetix, Inc. has a 12-month low of $0.67 and a 12-month high of $74.29.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned 0.84% of Onconetix as of its most recent filing with the Securities and Exchange Commission (SEC). 23.89% of the stock is currently owned by hedge funds and other institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.